This suggested that CDKL3 may reshape the TME by regulating these chemokines and chemokine receptors, leading to the infiltration of immunosuppressive cells, ultimately affecting the response to immunotherapy and the promotion of tumor progression. The gene discussed is CDKL3; the disease is neoplasm.